Xlife Sciences AG (XSWX:XLS) Other Operating Expense: CHF29.87 Mil (TTM As of Dec. 2025)


XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF18.55
GF Value CHF7.27
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Other Operating Expense?

Xlife Sciences AG XSWX:XLS -4.38% 53 Other Operating Expense is CHF29.87 Mil as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.27 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's Other Operating Expense for the six months ended in Dec. 2025 was CHF21.06 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF29.87 Mil.

Xlife Sciences AG's quarterly Other Operating Expense declined from Dec. 2024 (CHF9.15 Mil) to Jun. 2025 (CHF8.81 Mil) but then increased from Jun. 2025 (CHF8.81 Mil) to Dec. 2025 (CHF21.06 Mil).

Xlife Sciences AG's annual Other Operating Expense declined from Dec. 2023 (CHF18.51 Mil) to Dec. 2024 (CHF17.93 Mil) but then increased from Dec. 2024 (CHF17.93 Mil) to Dec. 2025 (CHF29.87 Mil).

Xlife Sciences AG Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Other Operating Expense Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial 2.84 19.29 18.51 17.93 29.87

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.15 8.80 9.15 8.81 21.06
XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF29.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of CHF29.87 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a Other Operating Expense of CHF29.87 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Other Operating Expense too high?
Xlife Sciences AG's current Other Operating Expense is CHF29.87 Mil. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Other Operating Expense compare to VRTX and REGN?
Xlife Sciences AG's Other Operating Expense of CHF29.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Other Operating Expense is CHF29.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.27, compared to a current price of CHF18.55 — trading 155.2% above its estimated fair value. The current Other Operating Expense is CHF29.87 Mil. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Other Operating Expense is CHF29.87 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF18.55 is trading 155.2% above its estimated GF Value™ of CHF7.27. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Other Operating Expense: CHF29.87 Mil
  • GF Value™: CHF7.27 vs. price of CHF18.55 (155.2% above fair value)
  • GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.55
Price
CHF7.27
GF Value